The identification of key regulatory factors that control osteoclastogenesis is important. Accumulating evidence indicates that circular RNAs (circRNAs) are discrete functional entities. However, the complexities of circRNA expression as well as the extent of their regulatory functions during osteoclastogenesis have yet to be revealed. Here, based on circular RNA sequencing data, we identified a circular RNA, circFam190a, as a critical regulator of osteoclast differentiation and function. During osteoclastogenesis, circFam190a is significantly upregulated. In vitro, circFam190a enhanced osteoclast formation and function. In vivo, overexpression of circFam190a induced significant bone loss, while knockdown of circFam190a prevented pathological bone loss in an ovariectomized (OVX) mouse osteoporosis model. Mechanistically, our data suggest that circFam90a enhances the binding of AKT1 and HSP90β, promoting AKT1 stability. Altogether, our findings highlight the critical role of circFam190a as a positive regulator of osteoclastogenesis, and targeting circFam190a might be a promising therapeutic strategy for treating pathological bone loss.
1 March 2018 in The American Journal of the Medical Sciences
Osteoporosis is one of the major health problems characterized by decreased bone density and increased risk of fractures. Nowadays, the treating strategies against osteoporosis are efficient, but still have some drawbacks. Micheliolide, a guaianolide sesquiterpene lactone isolated from Michelia compressa and Michelia champac, has been reported to have anti-inflammatory effects. Here, our data suggest that Micheliolide could protect mice from ovariectomy induced bone loss. According to the Micro-CT scan and histomorphometry quantification data, Micheliolide treatment inhibits excessive osteoclast bone resorption without affecting bone formation in estrogen deficiency mice. Consistently, our data suggest that Micheliolide could inhibit osteoclastogenesis in vitro. Additionally, we confirmed that Micheliolide inhibits osteoclasts formation via inhibiting P38 MAPK signaling pathway, and P79350 (a P38 agonist) could rescue this effect. In summary, our data suggest that Micheliolide could ameliorate estrogen deficiency-induced bone loss via attenuating osteoclastogenesis. Hence, Micheliolide could be used as a novel anti-resorptive agent against osteoporosis.
Implant-related infections (IRIs) present a significant challenge in clinical treatment because of the formation of biofilms. The complex architecture of biofilms not only impedes antibiotic penetration, fostering the evolution of multidrug resistance in bacteria under minimal selective pressure but also suppresses the antimicrobial activity of macrophages and induces their pyroptosis in large quantities. This excessive pyroptosis impairs the collective immune function of macrophages, enabling pathogens to evade immune system clearance and rendering infection difficult to eradicate. Existing treatment strategies often necessitate extensive surgical debridement, which not only causes significant harm to patients' physiological health and quality of life but also results in limited therapeutic outcomes. To address these challenges, this study developed a mesoporous silica nanoparticle system (MRL) modified with the RGD (Arginine-Glycine-Aspartic acid) tripeptide and loaded with the antimicrobial peptide LL-37. The LL-37 released from MRL can not only directly disrupt bacterial cell membranes, preventing bacteria from developing resistance through conventional mutation mechanisms, but also enhance antimicrobial activity by modulating macrophage polarization toward the M1 phenotype. However, LL-37 may induce and exacerbate macrophage pyroptosis within biofilms. Therefore, we modified the nanoparticles with RGD to increase macrophage viability and reduce their number of deaths, thereby alleviating the immunosuppression caused by excessive macrophage pyroptosis. In vitro and in vivo experiments demonstrated that MRL, while preserving the antimicrobial activity and immunomodulatory function of LL-37, significantly reduced macrophage pyroptosis and protected the collective immune activity of macrophages. Thus, the fine-tuned regulation of immune response was achieved, providing new insights and strategies for the treatment of IRIs.
In osteoporotic bones, the stability of orthopedic implants is compromised, and excessive M1 macrophage polarization at the bone‐implant interface disrupts bone‐immune homeostasis, leading to implant loosening or failure. To address this, this study develops a bionic magnesium alloy internal fixation coating inspired by the “brick‐and‐mortar” structure of pearl, aiming to improve bone‐implant integration and vascularization in osteoporotic conditions. The multifunctional coating consists of a calcium phosphate (Ca‐P) “brick” layer, which serves as a mineralization template and corrosion barrier, and fibronectin‐mimetic peptides (Fn‐mimetic peptides) as the “mortar” to promote cell adhesion, regulate immune responses, and stimulate angiogenesis. This bionic multilayer structure not only alleviates oxidative stress in the osteoporotic microenvironment but also fosters immune regulation‐osteogenesis coupling and improves the bone‐vascular‐immune microenvironment. It precisely controls the degradation rate of Mg alloys and enhances tissue repair. The CaP layer reduces rapid degradation and prevents hydrogen gas release and local alkalinization, whereas Fn‐mimetic peptides enhance early bone integration and vascularization. The synergistic effect of the magnesium alloy implant and bionic coating significantly improved bone implant stability, regeneration, and vascularization, as demonstrated in osteoporotic rat models, offering a promising strategy for the design of bone repair materials under pathological conditions.
An oxygen vacancy-containing hafnium oxide/polyetheretherketone composite exhibits not only antitumor and antimicrobial properties because of its photothermal performance but also a pro-osteogenic effect both in vitro and in vivo .